Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR3 | O14843 | 3/20 | 1.00 |
| ▸ | HDAC3 | O15379 | 2/20 | 1.00 |
| ▸ | HDAC1 | Q13547 | 2/20 | 1.00 |
| ▸ | HDAC2 | Q92769 | 2/20 | 1.00 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 1.00 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.61 |
| ▸ | GPR84 | Q9NQS5 | 7/20 | 0.58 |
| ▸ | PPARG | P37231 | 7/20 | 0.58 |
| ▸ | PPARD | Q03181 | 7/20 | 0.58 |
| ▸ | PPARA | Q07869 | 7/20 | 0.58 |
| ▸ | HDAC11 | Q96DB2 | 5/20 | 0.58 |
| ▸ | TSHR | P16473 | 5/20 | 0.58 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.58 |
| ▸ | TLR2 | O60603 | 2/20 | 0.58 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.58 |
| ▸ | FABP4 | P15090 | 2/20 | 0.58 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.58 |
| ▸ | SLC22A8 | Q8TCC7 | 1/20 | 0.58 |
| ▸ | MEN1 | O00255 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Butyric Acid SCHEMBL1330379 | 1.00 | — | — | |
| Butyric Acid SCHEMBL991717 | 1.00 | FFAR3 (1.00) | FFAR3HDAC3HDAC1HDAC2HDAC8 | |
| Butyric Acid SCHEMBL320515 | 1.00 | FFAR3 (1.00) | FFAR3HDAC3HDAC1HDAC2HDAC8 | |
| Butyric Acid SCHEMBL4446516 | 1.00 | FFAR3 (1.00) | FFAR3HDAC3HDAC1HDAC2HDAC8 | |
| Butyric Acid SCHEMBL1332215 | 1.00 | — | — | |
| Butyric Acid SCHEMBL5703921 | 1.00 | FFAR3 (1.00) | FFAR3HDAC3HDAC1HDAC2HDAC8 | |
| Butyric Acid SCHEMBL8458708 | 1.00 | FFAR3 (1.00) | FFAR3HDAC3HDAC1HDAC2HDAC8 | |
| Butyric Acid SCHEMBL8457839 | 1.00 | FFAR3 (1.00) | FFAR3HDAC3HDAC1HDAC2HDAC8 | |
| Butyric Acid SCHEMBL20678495 | 1.00 | — | — | |
| Butyric Acid SCHEMBL2503 | 1.00 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 298 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3368600-B1 | WATER-BASED COATING COMPOSITIONS | SUN CHEMICAL CORP (US) | 2020-06-10 | — | — | EP | claimed |
| US-20140080769-A1 | SUBSTRATE REDUCTION THERAPY | THE CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVERSITY OF OXFORD (GB) | 2014-03-20 | — | — | US | claimed |
| EP-1808467-B1 | Liquid silicone rubber coating composition, curtain airbag and making method | SHINETSU CHEMICAL CO (JP) | 2014-03-05 | — | — | EP | claimed |
| EP-1968991-B9 | BIS-PLATINUM COMPLEXES WITH ANTITUMOR ACTIVITY | CELL THERAPEUTICS INC SEDE SECONDARIA (IT) | 2012-08-08 | — | — | EP | claimed |
| EP-1968991-B1 | BIS-PLATINUM COMPLEXES WITH ANTITUMOR ACTIVITY | CELL THERAPEUTICS INC SEDE SECONDARIA (IT) | 2012-01-18 | — | — | EP | claimed |
| US-20100204162-A1 | SUBSTRATE REDUCTION THERAPY | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | 2010-08-12 | — | — | US | claimed |
| EP-2182936-A2 | SUBSTRATE REDUCTION THERAPY | THE CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVERSITY OF OXFORD (GB) | 2010-05-12 | — | — | EP | claimed |
| US-20100022620-A1 | EPITOPE REDUCTION THERAPY | ISIS INNOVATION LIMITED (GB) | 2010-01-28 | — | — | US | claimed |
| WO-2009141627-A1 | TREATING NIEMANN-PICK DISEASE TYPE C AND RELATED DISORDERS BY ELEVATING INTRACELLULAR CALCIUM | ISIS INNOVATION LIMITED (GB) | 2009-11-26 | — | — | WO | claimed |
| US-7612093-B2 | Compositions of treating hepatitis virus infections with N-substituted-1,5-dideoxy-1,5-imino-D-glucitol compounds in combination therapy | UNITED THERAPEUTICS CORPORATION (US) | 2009-11-03 | — | — | US | claimed |
| US-5798366-A | Method for treatment of CNS-involved lysosomal storage diseases | MONSANTO COMPANY (US) | 1998-08-25 | — | — | US | claimed |
| WO-1998035685-A1 | USE OF N-SUBSTITUTED-1,5-DIDEOXY-1,5-IMINO-D-GLUCITOL COMPOUNDS IN COMBINATION THERAPY FOR TREATING HEPATITIS VIRUS INFECTIONS | G.D. SEARLE AND CO. (US) | 1998-08-20 | — | — | WO | claimed |
| WO-1998030219-A1 | METHOD FOR TREATMENT OF CNS-INVOLVED LYSOSOMAL STORAGE DISEASES | MONSANTO COMPANY (US) | 1998-07-16 | — | — | WO | claimed |
| EP-0384366-B1 | Photosensitive recording element | BASF AG (DE) | 1995-02-15 | — | — | EP | claimed |
| EP-0367748-B1 | Novel antiviral compounds | SEARLE & CO (US) | 1995-01-25 | — | — | EP | claimed |
| US-5310745-A | Acylated derivatives of 1,5-dideoxy-1,5-imino-D-glucitol, AIDS | G. D. SEARLE & CO. (US) | 1994-05-10 | — | — | US | claimed |
| US-5003072-A | Viricides | G. D. SEARLE & CO. (US) | 1991-03-26 | — | — | US | claimed |
| EP-0367748-A2 | Novel antiviral compounds | G.D. SEARLE & COMPANY (US) | 1990-05-09 | — | — | EP | claimed |
| US-4407821-A | LINOLENIC ACID OR ESTER, TRIGLYCERIDES | ROUSSEL UCLAF (FR) | 1983-10-04 | — | — | US | claimed |
| US-4009199-A | IMPREGNATION OF SILICA GEL CATALYST WITH ALUMINUM-TITANIUM-ZINC-TIN COMPOUNDS | CHEMISCHE WERKE HULS AKTIENGESELLSCHAFT (DT) | 1977-02-22 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100204162-A1 | SUBSTRATE REDUCTION THERAPY | GBA1, SPTLC2, NPC1L1 | FFAR3 1029/4885HDAC3 1332/4885HDAC1 1089/4885 |
| US-20140080769-A1 | SUBSTRATE REDUCTION THERAPY | GBA1, SPTLC2, NPC1L1 | FFAR3 1029/4885HDAC3 1332/4885HDAC1 1089/4885 |
| US-20100022620-A1 | EPITOPE REDUCTION THERAPY | UGCG, GBA1, ENGASE | FFAR3 1001/4885HDAC3 1504/4885HDAC1 1234/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.